ovarian cancer
Conditions
Interventions
Case series:Apatinib, 250 mg qd, po
standard chemotherapy
Sponsors
Daping Hospital
Eligibility
Sex/Gender
Female
Age
25 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. aged 25 to 75 years; 2. The pathological diagnosis of recurrent or metastatic ovarian cancer (including epithelial ovarian cancer, fallopian tube carcinoma or primary peritoneal carcinoma); 3. Eastern Cooperative Oncology Group (ECOG) performance status 0-1; 4. expected survival time =3 months; 5. Patients must have adequate organ function as defined by the following criteria: With normal blood routine examination (without blood transfusion during 14 daysunused g-csf and other hematopoietic stimulating factor correct): HB=90g/L; ANC =1.5×10^9/L; PLT =80×10^9/L. Biochemical examination: a total bilirubin (TBil) of =1.5 upper normal limitation (UNL); a alanine aminotransferase (ALAT) and aspartate aminotransferase (ASAT) of =2.5 UNL or =5 UNL in case of liver metastasis; a creatinine (Cr) of = 1.25 UNL; a creatinine clearance rate = 45ml/min (Cockcroft-Gault); 6. With written informed consent signed voluntarily by patients themselves. With good compliance and agree to accept follow-up of disease progression and adverse events.
Exclusion criteria
Exclusion criteria: 1. Uncontrolled hypertension 2. Suffered from grade II or above myocardial ischemia or myocardial infarction, uncontrolled arrhythmias; 3. With abnormal coagulation function bleeding tendency or treating with thrombolysis and anticoagulation; 4. History of clinically relevant major bleeding event (e.g. gastrointestinal hemorrhage, bleeding ulcer, occult blood = (++), and vasculitis) =++, or urine protein in 24 hours> 1.0g; 9. Accumulation of coelomic fluid (e.g. pleural effusion, ascites fluid, cardiac effusion) requiring treatment; 10. History of uncontrolled psychotropic drug abuse or mental disorders; 11. Prior VEGFR inhibitor treatment; 12. Other malignancy within Before or at the same time other than basal cell skin cancer, or carcinoma in situ of the cervix.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| PFS; | — |
Secondary
| Measure | Time frame |
|---|---|
| OS;ORR;DCR;Safety; | — |
Countries
China
Contacts
Public ContactFeng Jin
Daping Hospital
Outcome results
None listed